NASDAQ:ANAB AnaptysBio Q2 2026 Earnings Report $54.99 -0.21 (-0.38%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast AnaptysBio EPS ResultsActual EPS$5.11Consensus EPS -$0.47Beat/MissBeat by +$5.58One Year Ago EPSN/AAnaptysBio Revenue ResultsActual Revenue$27.49 millionExpected Revenue$14.06 millionBeat/MissBeat by +$13.43 millionYoY Revenue GrowthN/AAnaptysBio Announcement DetailsQuarterQ2 2026Date9/21/2026TimeBefore Market OpensConference Call DateMonday, September 21, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) AnaptysBio Earnings HeadlinesAnaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update46 minutes ago | globenewswire.comAlphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)September 9, 2026 | insidermonkey.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 21 at 1:00 AM | Profits Run (Ad)Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 1, 2026 | globenewswire.comGSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug ControlAugust 17, 2026 | finance.yahoo.comAnaptysBio, Inc.August 12, 2026 | edition.cnn.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases. The company uses its proprietary antibody discovery and engineering capabilities to develop therapeutic candidates, with programs advancing through clinical development and partnerships. Its research has historically included immuno-oncology programs as well as treatments for diseases such as rheumatoid arthritis and inflammatory bowel disease. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also generated value through licensing and collaboration agreements. Its antibody-discovery platform contributed to dostarlimab, an anti-PD-1 therapy developed by Tesaro and now marketed by GSK as Jemperli for certain cancer indications. The company’s operations and clinical development activities are primarily centered in the United States, with studies and commercial partnerships extending internationally. AnaptysBio is led by Chief Executive Officer Hamza Suria.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
